Revocation of vaccine mandates – effective 15th March
90% of respondents supported revocation of the vaccine mandate, in a public consultation exercise carried out in February 2022. The UK Government has today (March 1st) published its… read more.
90% of respondents supported revocation of the vaccine mandate, in a public consultation exercise carried out in February 2022. The UK Government has today (March 1st) published its… read more.
Moderna, Inc., announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna’s mRNA COVID-19 vaccine, Spikevax, in a 50 µg… read more.
A patient living with HIV who received a blood stem cell transplant for high-risk acute myeloid leukemia has been free of the virus for 14 months after stopping… read more.
Communities in the North West of England experienced more than three times the excess years of life lost in the South West. The impact of the COVID-19 pandemic… read more.
Critically ill COVID-19 patients already on mechanical ventilation or extracorporeal membrane oxygenation have achieved a significantly higher rate of survival when randomized to receive baricitinib, a treatment for… read more.
For at least six months after COVID-19 vaccination, antibodies produced by immune cells become steadily more formidable and more precisely targeted against the virus that causes COVID-19, according… read more.
The third wave of the COVID-19 pandemic in the summer of 2021 spread far faster in rural America, much of which has low rates of vaccination. A new… read more.
Incyte has announced that the FDA has approved Jakafi (ruxolitinib) for treatment of chronic graft-versus-host disease (GVHD) after failure of one or two lines of systemic therapy in… read more.
University of Illinois Chicago researchers have developed a compound that may one day offer hope for pancreatic cancer treatment. A pre-clinical study of the experimental compound shows that… read more.
Pregnant women with COVID-19 appear to be at greater risk for common pregnancy complications — in addition to health risks from the virus — than pregnant women without… read more.
ViiV Healthcare presented positive interim data from the Phase III CARISEL study of Vocabria + Rekambys (cabotegravir + rilpivirine), which was initiated and conducted during the COVID-19 pandemic…. read more.
With low rates of disease flare and reactogenicity after vaccination, the study findings are reassuring for both patients and clinicians, according to Dr Caoilfhionn Connolly, Rheumatology Fellow at… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.